Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Elizabeth Hill and Mark Rubinstein.
Elizabeth Hill
Connection Strength
0.405
Mark Rubinstein
  1. Phase I Trial Characterizing the Pharmacokinetic Profile of N-803, a Chimeric IL-15 Superagonist, in Healthy Volunteers. J Immunol. 2022 03 15; 208(6):1362-1370.
    View in: PubMed
    Score: 0.206
  2. ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial. Lancet Oncol. 2018 05; 19(5):694-704.
    View in: PubMed
    Score: 0.157
  3. Thioredoxin-1 improves the immunometabolic phenotype of antitumor T cells. J Biol Chem. 2019 06 07; 294(23):9198-9212.
    View in: PubMed
    Score: 0.042
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.